Daily Injections Discontinue daily GLP-1 injections at least 24 hours prior to surgery
If we are withholding a potentially, you know, useful treatment for people that we kind of get better data on this
Why this matters: improper injection technique can reduce bioavailability, increase localized adverse effects, and undermine therapeutic goals
Who Could Benefit Patients on GLP-1 receptor agonists struggling with unintended muscle loss Individuals seeking more functional or metabolic benefits from weight loss Providers concerned about sarcopenia or frailty during obesity treatment What Comes Next Monitor publication of full 52-week COURAGE trial data Evaluate long-term outcomes on both body composition and adverse events Prepare to integrate antibody therapies into future obesity protocolsif confirmed safe and effective Conclusion The interim findings from Regenerons COURAGE trial underscore a pivotal shift in how we think about weight lossmoving beyond just the number on the scale
Countries like China and India are experiencing a surge in demand for diabetes management solutions, supported by government initiatives aimed at improving healthcare infrastructure
In December 2014, it was deemed a suitable option for chronic weight management in addition to a calorie reduced diet and physical activity
